Before the patient has even completed their first consultation, a private prescription of medical cannabis could cost them hundreds of pounds per month. Is cannabis covered under insurance? Not always. In most cases, coverage is dependent on factors such as the insurance company, whether it’s a public or private payer, diagnosis, legal status of the product and whether other treatments have failed.
Patients make the financial distinction. Operators and investors face a similar issue. The reimbursement will determine who is realistically able to afford the treatment. It also helps predict demand and whether or not medical cannabis continues as a private-pay specialty.
Does cannabis insurance cover the UK?
NHS-funded medicinal cannabis is still highly restricted in Great Britain. NHS may prescribe certain cannabis-based medications for specific ailments, under the supervision of a specialist and with clinical advice. This includes products that are prescribed for severe forms of childhood epilepsy and multiple sclerosis-related spasticity, as well as chemotherapy-related nausea or vomiting.
It is important to note that this does not mean a general reimbursement for the cannabis flowers, oils, or customized formulations prescribed in private clinics. The majority of patients in the UK who use unlicensed medicinal cannabis pay for it themselves. Although the physician may have prescribed it and it may be legal, private health insurers do not generally cover this as part of their standard benefits.
Practical reasons are behind this caution. Insurance companies often require that a medication has a clear indication and a cost profile they can predict, as well as sufficient proof for the disease being treated. The prescribing of cannabis for medical purposes often requires unlicensed product, dose titrations and clinical data that are in the early stages. Those factors complicate conventional claims evaluation and underwriting.
Some policies cover certain elements, like a consultation or diagnostic test, but not the actual cannabis medication. Other policies do not cover controlled drugs, non-licensed medications, chronic pain management, or treatments that aren’t routinely offered through the NHS. It is more important to look at the policy text than any headline claims from clinics or brokers.
The questions UK claimants should ask
The patient should inquire if their insurance covers separate costs for the prescription, consultation, and dispensing fees. Patients should check if pre-authorisation, outpatient drugs excluded from the policy and the actual condition is covered.
The refusal of a treatment does not mean that it is clinically ineffective or illegal. It means that your insurance policy does not cover the medicine. If a patient believes that a cannabis-based medication has been prescribed to treat an approved condition, they should ask for a written statement.
The public reimbursement system in Europe: A fragmented view
In Europe, it is more important to ask whether an insurance company will reimburse cannabis prescribed by a doctor, or whether the state-run health care system will. No single European solution exists.
Germany’s statutory healthcare system reimburses medical cannabis when certain conditions are met. The 2017 reform has allowed eligible patients to request coverage for cannabis, including cannabis extracts and cannabis-based medications, if they suffer from a serious disease, have no other suitable treatment, and have reasonable expectations of benefit.
Although the rule may seem broad, it can actually be very demanding. Insurance companies may ask for clinical documentation, prior approval and proof that the standard therapy has been used, but was ineffective, or had unacceptable side effects. Initial applications may be denied, and doctors might be reluctant to write prescriptions when reimbursement paperwork, budget scrutiny, or uncertainty about product selection adds extra workload.
Germany is also a good example of a trade-off that’s central to the debate on reimbursement. A wider coverage may improve access for patients, but payers will often react with more restrictive clinical controls, prescription audits, and increased price pressure. A reimbursed cannabis market can be bigger than the private-pay one, but it is also more susceptible to changes in regulations and purchasing dynamics.
The approaches of other European systems are markedly diverse. Some countries only fund a small number of cannabis-based pharmaceutical medicines for specific indications. Some countries offer imported or magistral cannabis products, which are available privately. National regulations can differ from local or regional commissioning decisions. This makes claims of “European coverage”, which is a broad statement, unreliable.
Cannabis prescriptions versus licensed medicine
It is important to consider the status of the drug as well as its diagnosis. An approved medicine by the national regulatory body for a particular condition will have a smoother reimbursement route than cannabis prescribed without its marketing authorization.
It does not follow that unlicensed prescriptions have no place in the medical field. When they feel there is a unmet medical need, and the product has a good evidence base, doctors may choose to prescribe an unlicensed product. When deciding whether to reimburse public funds or insurance companies, reimbursement authorities typically use a stricter standard. The public wants clarity about quality standards, cost effectiveness, and comparative benefits.
Cannabis flower has been a controversial topic. Payers may view the variability of product characteristics and dosing as obstacles to reimbursement. Patients and doctors might value the variety of chemovars, and its flexible administration. Some systems may cover extracts and pharmaceuticals more easily, but they’re not always guaranteed.
Insurers keep coming back to the question of evidence
Medical cannabis does not qualify as a single treatment. Cannabidiols, THC-dominant medicine, balanced extracts, and dried flowers can all have different risk profiles, evidence profiles, and uses. The positive results of a clinical trial in a particular product category or medical condition may not be applicable across all categories.
Regulators and payers accepted that the evidence was sufficient to license medicines for several highly-publicized indications. Evidence is mixed for chronic pain, anxiety and insomnia, as well as a variety of other reasons that people use private medical cannabis. Although patients may have reported a positive experience, insurers will often look at controlled trials and treatment guidelines as well as health-economic analyses before including a new therapy in routine coverage.
It’s frustrating. Those most likely to turn to cannabis as a treatment option may already have tried all of their options. But, because there is no consistent reimbursement system in place, they are forced into paying for it privately. The cost can affect the patient’s adherence to treatment, their dosage and even whether they remain in care.
How to create a better reimbursement case
Cannabis as an integral part of the treatment plan is more convincing than cannabis used alone. The prescribing expert should include the following information: diagnosis, symptoms, prior therapies, side effects, goals of treatment, and scheduled review.
Documentation alone cannot overcome an exclusion from the insurance policy. Questions to ask are whether or not the treatment falls under the policy, whether it is covered by the drug and if there was a referral required.
Patients may be able to appeal a refusal by a payer public or an insurer. The appeal can have a short deadline, but it is more effective if the patient addresses directly the reason given for the refusal. A clinician can help if the payer is citing insufficient proof. They could explain failed treatments and what benefit they expect. It may be better to change the formulation of the product or pursue a licensed substitute than continue to contest the decision.
Coverage of the Cannabis market
The reimbursement policy affects more than just individual claims. Patients who are able to afford monthly prescription costs can quickly grow a market that is dependent on private prescriptions. However, the growth may be uneven and sensitive towards household budgets. The reimbursement path can increase access and shift commercial power to products that are compliant with payers’ requirements for data, consistency in manufacturing and pricing.
The signal that European business should be watching is not just whether or not a nation legalises medicinal cannabis. The key question is how health authorities will define eligibility, set prescribing guidelines, collect clinical data and implement a payment system. Many patients may not be able to afford medical cannabis if reimbursement isn’t available.
Prior to choosing a treatment, it is important that patients consider the cost of their options. You should ask about coverage, obtain any necessary approvals in writing, and prepare for possible self-funding. Financial access will continue to be a major policy issue until reimbursement catches-up with demand for clinical services in many jurisdictions.